Skip to main content

Table 2 Prognostic factors for OS in all patients (n = 176)

From: Feasibility of linac-based fractionated stereotactic radiotherapy and stereotactic radiosurgery for patients with up to ten brain metastases

 

Univariate analysis

Multivariate analysis

 

HR (95% CI)

p value

HR (95% CI)

p value

Number of BMs

A (1)

0.57 (0.38–0.86)

0.007

0.59 (0.39–0.91)

0.016

B (2–4)

Ref

–

Ref

–

C (5–10)

1.35 (0.84–2.17)

0.217

1.00 (0.60–1.66)

0.997

Age (years)

 < 65

Ref

-

Ref

-

 ≥ 65

1.21 (0.80–1.81)

0.368

1.14 (0.75–1.73)

0.554

Gender

Female

Ref

–

Ref

–

Male

1.74 (1.20–2.51)

0.003

1.71 (1.16–2.53)

0.007

Primary site

Lung

1.56 (0.57–4.29)

0.386

1.08 (0.37–3.13)

0.885

GI

4.12 (1.39–12.12)

0.011

2.43 (0.77–7.64)

0.129

Breast

Ref

–

Ref

–

Others

2.26 (0.79–6.47)

0.130

1.61 (0.53–4.90)

0.401

KPS

 ≥ 80

Ref

–

Ref

–

 ≤ 70

2.04 (1.42–2.91)

 < 0.001

1.63 (1.10–2.41)

0.015

Extracranial lesions

Controlled

Ref

–

Red

–

Uncontrolled

3.35(2.06–5.43)

 < 0.001

2.97 (1.79–4.92)

 < 0.001

fSRT or SRS

SRS

Ref

–

Ref

–

fSRT

1.31 (0.91–1.87)

0.142

0.92 (0.58–1.46)

0.728

Total PTV volume (cm3)

1 (≥ 15)

1.98 (1.25–3.19)

0.086

1.35 (0.74–2.49)

0.330

2 (≥ 4, < 15)

1.45 (0.95–2.22)

0.003

1.30 (0.81–2.08)

0.278

3 (< 4)

Ref

–

Ref

–

  1. BMs Brain metastases, GI Gastrointestinal cancers, KPS Karnofsky performance status, fSRT Fractionated stereotactic radiotherapy, SRS Stereotactic radiosurgery, PTV Planning target volume
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us